Head-to-head evidence
Bexagliflozin vs janagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Bexagliflozin · Brenzavvy
Marketed by Theracos
NCT02558296 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo-controlled trial with 1,700 participants, and its primary HbA1c comparison was statistically significant in favor of bexagliflozin. The grade is moderate because HbA1c is a surrogate measure rather than a hard clinical outcome.
Next expected readout: March 2029 · NCT07547878 (registry estimate)
janagliflozin
Developed by Sihuan Pharmaceutical Holdings
NCT03811548 · Phase 3 · status unknown
This randomized, double-blind, placebo-controlled trial enrolled 442 patients and measured change in HbA1c, a standard diabetes efficacy measure, at 24 weeks. Both the 25 mg and 50 mg doses of janagliflozin significantly outperformed placebo (p<0.001 for both), exceeding the trial's pre-specified superiority margin.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bexagliflozin's landscape · janagliflozin's landscape